1

Biotechnology Companies in the News Editor’s Note: The home page of the BioNJ Web site provides an up-to-the-minute headline service where readers can access press releases issued by New Jersey-based biotechnology companies. Go to the “New Jersey Biotechnology Company News” section on the BioNJ home page (www.BioNJ.org) to read the latest news. Companies wishing to appear in the Biolines Biotechnology Companies in the News section are encouraged to send their news releases to BioNJ via e-mail at BioNJ@BioNJ.org. February 25 Aerie Pharmaceuticals Announces Study Results Supporting Additional Mechanism of Action for Lead Glaucoma Drug Candidate AR-13324 http://finance.yahoo.com/news/aerie-pharmaceuticals-announces-study-results-113000601.html February 24 Bristol-Myers Squibb Receives U.S. FDA Breakthrough Therapy Designation for All-Oral Daclatasvir Dual Investigational Regimen for Chronic Hepatitis C http://news.bms.com/press-release/bristol-myers-squibb-receives-us-fda-breakthrough-therapy-designation-all-oral-daclata Aerie Pharmaceuticals Names Marvin J. Garrett as Vice President, Regulatory Affairs and Quality Assurance http://finance.yahoo.com/news/aerie-pharmaceuticals-names-marvin-j-213000449.html February 21 In a Subanalysis, Eliquis® (apixaban) Reduced the Risk of Stroke and Demonstrated Fewer Major Bleeding Events versus Warfarin Consistently across Age Groups, Including Older Patients with Nonvalvular Atrial Fibrillation http://news.bms.com/press-release/rd-news/subanalysis-eliquis-apixaban-reduced-risk-stroke-and-demonstrated-fewer-major- February 20 Antares Pharma Announces Positive Results from the VIBEX QuickShot Pharmacokinetic Study in Testosterone Deficient Men http://www.businesswire.com/news/home/20140220005221/en/Antares-Pharma-Announces-Positive-Results-VIBEX-QuickShot FDA Accepts for Review Merck’s Biologics License Application for V503, Investigational 9-valent Human Papillomavirus Vaccine http://www.thestreet.com/story/12421922/1/fda-accepts-for-review-merck8217s-biologics-license-application-for-v503-investigational-9-valent-human-papillomavirus-vaccine.html

2

Zoetis Will Hold Its First Annual Meeting of Shareholders on May 13 http://www.marketwatch.com/story/zoetis-will-hold-its-first-annual-meeting-of-shareholders-on-may-13-2014-02-20 Merck to Participate in the Citi 2014 Healthcare Conference http://www.mercknewsroom.com/news-release/corporate-news/merck-participate-citi-2014-healthcare-conference February 19 Antares Pharma to Participate in the 2014 RBC Capital Markets’ Global Healthcare Conference http://finance.yahoo.com/news/antares-pharma-participate-2014-rbc-120000450.html Insmed Provides Interim Update from Two-Year, Open-Label Extension Study of ARIKACE to Treat Pseudomonas aeruginosa in Cystic Fibrosis Patients http://files.shareholder.com/downloads/INSMED/1395905095x0x726791/81813ac5-80c2-4be9-8b0b-fe41548b3a5b/INSM_News_2014_2_19_General.pdf Aerie Pharmaceuticals to Present at the RBC Capital Markets Global Healthcare Conference http://www.businesswire.com/news/home/20140219005005/en/Aerie-Pharmaceuticals-Present-RBC-Capital-Markets-Global Ezose Sciences Receives Grant from Michael J. Fox Foundation to Use GlycanMap® Technology in Parkinson’s Research http://www.tmcnet.com/usubmit/2014/02/19/7684279.htm Jubilant Biosys Announces Expansion of Drug Discovery Alliance with Janssen Pharmaceutica http://www.businesswire.com/news/home/20140219005079/en/Jubilant-Biosys-Announces-Expansion-Drug-Discovery-Alliance February 18 Senesco Technologies Reports Second Quarter of Fiscal Year 2014 Financial Results http://www.businesswire.com/news/home/20131115005034/en/Senesco-Technologies-Reports-Quarter-Fiscal-Year-2014 Update Pharma Receives Orphan Drug Approval http://www.businesswire.com/news/home/20140218006775/en/Update-Pharma-Receives-Orphan-Drug-Approval NPS Pharmaceuticals Reports Fourth Quarter and Full-Year 2013 Financial Results and Financial Outlook for 2014 http://www.npsp.com/media?trxml_v=nrd&trxml_nr_id=1900956 Bard to Present at the Raymond James Institutional Investor Conference http://investorrelations.crbard.com/phoenix.zhtml?c=91501&p=irol-newsArticle&ID=1900963&highlight=

3

February 17 MSD Animal Health Receives Marketing Authorization from European Commission for BRAVECTO™ (fluralaner) http://www.businesswire.com/news/home/20140217005140/en/MSD-Animal-Health-Receives-Marketing-Authorization-European Samaritan Healthcare & Hospice Names James M. D’Onofrio Vice President of Strategic Business Initiatives http://www.businesswire.com/news/home/20140217005101/en/Samaritan-Healthcare-Hospice-Names-James-M.-D%E2%80%99Onofrio OncLive Announces 2014 Giants of Cancer Care Nominations Now Open http://www.businesswire.com/news/home/20140218006447/en/OncLive-Announces-2014-Giants-Cancer-Care-Nominations February 13 Billion-Dollar Biotech Valuations Fueling New IPO Surge http://blogs.wsj.com/venturecapital/2014/02/13/billion-dollar-biotech-valuations-fueling-new-ipo-surge/tab/print/ Alvogen launches Inflectra in Europe with Hospira http://www.businesswire.com/news/home/20140213005477/en/Alvogen-launches-Inflectra-Europe-Hospira Celgene Corporation Board of Directors Recommends to Our Stockholders a Two-for-One Stock Split http://www.businesswire.com/news/home/20140213005695/en/Celgene-Corporation-Board-Directors-Recommends-Stockholders-Two-for-One February 11 Pacira Pharmaceuticals, Inc. Announces Timing for 2013 Financial Results Webcast and Conference Call http://finance.yahoo.com/news/pacira-pharmaceuticals-inc-announces-timing-113000227.html Celgene Corporation to Present at Investor Conferences in February and March http://finance.yahoo.com/news/celgene-corporation-present-investor-conferences-133000529.html Dr. James Brown, COO, REGENX, Elected to SAFE-BioPharma Board of Directors http://www.businesswire.com/news/home/20140211005268/en/Dr.-James-Brown-COO-REGENX-Elected-SAFE-BioPharma February 10 Protalex Announces Interim Findings from U.S. Phase 1(b) Trial of PRTX-100 in Active Rheumatoid Arthritis Patients http://www.businesswire.com/news/home/20140210005165/en/Protalex-Announces-Interim-Findings-U.S.-Phase-1 Bard to Present at Citi 2014 Global Healthcare Conference http://finance.yahoo.com/news/bard-present-citi-2014-global-210500289.html

4

February 6 ZRG Partners Life Sciences Hiring Index Shows Modest Gains in 4th Quarter http://www.businesswire.com/news/home/20140206005994/en/ZRG-Partners-Life-Sciences-Hiring-Index-Shows The Medicines Company to Announce Fourth Quarter and Full Year 2013 Financial Results on Wednesday, February 19, 2014 http://ir.themedicinescompany.com/phoenix.zhtml?c=122204&p=irol-newsArticle&ID=1897864&highlight= The Medicines Company to Host Acute Cardiovascular Care Investor and Analyst Meeting on March 7 http://ir.themedicinescompany.com/phoenix.zhtml?c=122204&p=irol-newsArticle&ID=1897966&highlight= February 5 Merck Enters Strategic Collaborations with Amgen, Incyte and Pfizer to Evaluate Novel Combination Anti-cancer Regimens with MK-3475 http://www.mercknewsroom.com/news-release/oncology-newsroom/merck-enters-strategic-collaborations-amgen-incyte-and-pfizer-evaluat Merck Announces Fourth-Quarter and Full-Year 2013 Financial Results http://www.mercknewsroom.com/news-release/corporate-news/merck-announces-fourth-quarter-and-full-year-2013-financial-results Protalex Announces Appointment of Marco M. Elser to Its Board of Directors http://www.businesswire.com/news/home/20140205005063/en/Protalex-Announces-Appointment-Marco-M.-Elser-Board NPS Pharmaceuticals to Report 2013 Financial Results http://www.npsp.com/media?trxml_v=nrd&trxml_nr_id=1897346 Elusys Completes Enrollment in Three Phase 3 Safety Studies of Its Anthrax Anti-Toxin, Eti-204, in Adult Volunteers http://www.elusys.com/press_releases14/020514.html Bristol-Myers Squibb to Take Part in Leerink Swann Global Health Care Conference http://news.bms.com/press-release/financial-news/bristol-myers-squibb-take-part-leerink-swann-global-health-care-confe-0 BARDA Awards Contract Worth up to $90 Million to The Medicines Company/Rempex for Development of Gram-Negative Antibiotic http://ir.themedicinescompany.com/phoenix.zhtml?c=122204&p=irol-newsArticle&ID=1897071&highlight= February 3 Merck Announces Canadian Approval of GRASTEK®(Standardized Allergenic Extract, Timothy Grass (Phleum pratense) Sublingual Tablet) http://www.mercknewsroom.com/news-release/prescription-medicine-news/merck-announces-canadian-approval-grastek-standardized-aller

5

ADMA Biologics Expands Plasma Collection Operations of ADMA BioCenters http://www.businesswire.com/news/home/20140203006242/en/ADMA-Biologics-Expands-Plasma-Collection-Operations-ADMA Ablynx, Merck Launch Up to $2.3B Cancer Collaboration http://www.genengnews.com/gen-news-highlights/ablynx-merck-launch-up-to-2-3b-cancer-collaboration/81249449/ Pfizer breast cancer drug succeeds in mid-stage trial http://www.reuters.com/article/2014/02/03/us-pfizer-study-cancer-idUSBREA120OD20140203 Bristol-Myers Squibb Completes Previously Announced Sale of Global Diabetes Business to AstraZeneca http://news.bms.com/press-release/bristol-myers-squibb-completes-previously-announced-sale-global-diabetes-business-astr January 30 Celgene Reports Fourth Quarter and Full Year 2013 Operating and Financial Results http://ir.celgene.com/releasedetail.cfm?ReleaseID=822091 QPharma Announces Sales Effectiveness Workshop for Life Sciences http://www.businesswire.com/news/home/20140130006221/en/QPharma-Announces-Sales-Effectiveness-Workshop-Life-Sciences Bard Announces Fourth Quarter Results http://www.businesswire.com/news/home/20140130006374/en/Bard-Announces-Fourth-Quarter-Results Amicus Therapeutics Announces Presentations and Posters at Lysosomal Disease Network WORLD Symposium http://ir.amicustherapeutics.com/releasedetail.cfm?ReleaseID=822234 Elusys Reports Its Anti-Toxin Achieved 100% Survival Rate Following Anthrax Challenge in Pre-Treatment Animal Study http://www.elusys.com/press_releases14/013014.html PTC Therapeutics Announces that Stuart W. Peltz, Ph.D., CEO is the Recipient of the 2014 Dr. Sol J. Barer Award for Vision, Innovation and Leadership http://ir.ptcbio.com/ReleaseDetail.cfm?ReleaseID=822029 January 28 VaxInnate Receives $2.1 million from New Jersey’s Technology Business Tax Certificate Transfer Program http://www.businesswire.com/news/home/20140128005159/en/VaxInnate-Receives-2.1-million-Jersey%E2%80%99s-Technology-Business Lingraphica Promotes Two and Adds Speech-Language Pathologists to Its Clinical Team http://www.businesswire.com/news/home/20140128005255/en/Lingraphica-Promotes-Adds-Speech-Language-Pathologists-Clinical-Team

6

Merck Statement on FDA Advisory Committee Meeting for RAGWITEK™ (Short Ragweed Pollen Allergen Extract), an Investigational Sublingual Allergy Immunotherapy Tablet http://www.mercknewsroom.com/news-release/merck/merck-statement-fda-advisory-committee-meeting-ragwitek-short-ragweed-pollen-alle Lexicon to Present at the BIO CEO & Investor Conference http://www.lexpharma.com/news/press-releases/2313-alias.html January 24 Catalent Files Registration Statement for Initial Public Offering http://www.reuters.com/article/2014/01/24/nj-catalent-pharma-idUSnBw245639a+100+BSW20140124 PTC Therapeutics Provides Update On CHMP Opinion For Conditional Approval Of Ataluren For Nonsense Mutation Duchenne Muscular Dystrophy http://ir.ptcbio.com/ReleaseDetail.cfm?ReleaseID=820977 PTC Therapeutics Expands Management Team http://ir.ptcbio.com/ReleaseDetail.cfm?ReleaseID=820975 Bristol-Myers Squibb Reports Fourth Quarter and Full Year 2013 Financial Results http://news.bms.com/press-release/financial-news/bristol-myers-squibb-reports-fourth-quarter-and-full-year-2013-financia January 23 Protalex Announces Completion of $2.8 Million Private Placement http://www.businesswire.com/news/home/20140123005085/en/Protalex-Announces-Completion-2.8-Million-Private-Placement John Theurer Cancer Center Announces Positive Results with New Targeted Biological in Indolent Non-Hodgkin Lymphoma http://www.businesswire.com/news/home/20140123005189/en/John-Theurer-Cancer-Center-Announces-Positive-Results Wipro Cited as a Leader in Worldwide Life Science Manufacturing and Supply Chain ITO by Independent Research Firm http://www.businesswire.com/news/home/20140123005441/en/Wipro-Cited-Leader-Worldwide-Life-Science-Manufacturing STENTYS 2013 Annual Revenues Up 34% From 2012 http://www.businesswire.com/news/home/20140123005876/en/STENTYS-2013-Annual-Revenues-34-2012 Derma Sciences Announces Commencement of Public Offering of Common Stock http://www.businesswire.com/news/home/20140123006300/en/Derma-Sciences-Announces-Commencement-Public-Offering-Common

7

January 22 Celgene Corporation to Announce Fourth Quarter and Full Year 2013 Results on January 30, 2014 http://newsroom.celgene.com/press-release/corporate/celgene-corporation-announce-fourth-quarter-and-full-year-2013-results-janua Biocon Collaborates with Advaxis for ‘ADXS-HPV’ A Novel Cancer Immunotherapy http://www.businesswire.com/news/home/20140122005768/en/Biocon-Collaborates-Advaxis-%E2%80%98ADXS-HPV%E2%80%99-Cancer-Immunotherapy Giants of Cancer Care Awards Program Advisory Panel Grows by Leaps and Bounds http://www.businesswire.com/news/home/20140122006121/en/Giants-Cancer-Care-Awards-Program-Advisory-Panel AZ diabetes combo Xigduo approved in Europe http://www.pharmatimes.com/Article/14-01-22/AZ_diabetes_combo_Xigduo_approved_in_Europe.aspx Joint Program In Spinal Muscular Atrophy Enters First Stage Of Clinical Development http://ir.ptcbio.com/releasedetail.cfm?ReleaseID=820410 January 21 Advaxis Announces First Patient Dosed in Phase 1/2 Head and Neck Cancer Study http://www.businesswire.com/news/home/20140121005860/en/Advaxis-Announces-Patient-Dosed-Phase-12-Head IMS Health: Pharma Should Make Better Use of Social Media To Engage Patients and Improve the Use of Medicines http://www.imshealth.com/portal/site/imshealth/menuitem.c76283e8bf81e98f53c753c71ad8c22a/?vgnextoid=ebc072cc270b3410VgnVCM10000076192ca2RCRD&vgnextchannel=ba11e590cb4dc310VgnVCM100000a48d2ca2RCRD&vgnextfmt=default January 16 AstraZeneca and Bristol-Myers Squibb Diabetes Alliance Provides $5 Million Grant for American Diabetes Association's Pathway to Stop Diabetes Research Initiative http://news.bms.com/press-release/astrazeneca-and-bristol-myers-squibb-diabetes-alliance-provides-5-million-grant-americ January 15 Antares Pharma Announces Availability of OTREXUP (Methotrexate) Injection for Subcutaneous Use to Treat Rheumatoid Arthritis (RA) and Psoriasis in Adults, and Polyarticular Idiopathic Arthritis (pJIA) in Children http://www.businesswire.com/news/home/20140115005199/en/Antares-Pharma-Announces-Availability-OTREXUP-Methotrexate-Injection Advaxis Launches Online Communication Channels http://finance.yahoo.com/news/advaxis-launches-online-communication-channels-133000769.html

8

Merck Statement on FDA Advisory Committee for Vorapaxar, Merck’s Investigational Antiplatelet Medicine http://www.mercknewsroom.com/news-release/research-and-development-news/merck-statement-fda-advisory-committee-vorapaxar-mercks-i Amgen, MGH, Broad Form IBD Therapeutics Initiative http://www.genengnews.com/gen-news-highlights/amgen-mgh-broad-form-ibd-therapeutics-initiative/81249373/ January 14 Derma Sciences Enters the Skin Substitute Market with Licensing Agreement for Innovative Amniotic Membrane Wound Care Products http://www.thestreet.com/story/12237237/1/derma-sciences-enters-the-skin-substitute-market-with-licensing-agreement-for-innovative-amniotic-membrane-wound-care-products.html January 13 U.S. FDA Approves Farxiga™ (Dapagliflozin) Tablets for the Treatment of Adult Patients with Type 2 Diabetes http://news.bms.com/press-release/rd-news/us-fda-approves-farxiga-dapagliflozin-tablets-treatment-adult-patients-type-2- Merck Provides Update on Accelerated Strategic Actions for Growth at 32nd Annual J.P. Morgan Healthcare Conference http://www.mercknewsroom.com/news-release/corporate-news/merck-provides-update-accelerated-strategic-actions-growth-32nd-annual-j Merck Initiates Rolling Submission of U.S. Biologics License Application for MK-3475, an Investigational Anti-PD-1 Immunotherapy, in Patients with Advanced Melanoma http://www.mercknewsroom.com/news-release/oncology-newsroom/merck-initiates-rolling-submission-us-biologics-license-application-m Merck's anti-blood clot drug should be approved: FDA review http://www.reuters.com/article/2014/01/13/us-merck-vorapaxar-idUSBREA0C0SZ20140113 Celgene Corporation Announces 2014 Financial Outlook and Preliminary 2013 Results http://newsroom.celgene.com/press-release/corporate/celgene-corporation-announces-2014-financial-outlook-and-preliminary-2013-re Sanofi to buy 12 pct of Alnylam, expands rare-disease drug deal http://in.reuters.com/article/2014/01/13/sanofi-alnylam-idINL2N0KN0G120140113 Amicus Therapeutics Provides Full-Year 2014 Strategic Outlook and Financial Guidance http://files.shareholder.com/downloads/AMTX/2893799923x0x717980/8dec73ba-00cd-44d7-9600-9eddc4707a7d/FOLD_News_2014_1_13_General.pdf Lexicon Announces Focus on Late-Stage Development Programs and Preparation for Commercialization http://www.lexpharma.com/news/press-releases/2311-lexicon-announces-focus-on-late-stage-development-programs-and-preparation-for-commercialization.html

9

FDA Grants QIDP Designation to The Medicines Company's Investigational Antibiotic Carbavance http://ir.themedicinescompany.com/phoenix.zhtml?c=122204&p=irol-newsArticle&ID=1890146&highlight= Cyclacel Reviews 2013 Achievements and Announces Key Business Objectives for 2014 http://investor.cyclacel.com/releasedetail.cfm?ReleaseID=818766 Regeneron, Bayer to co-develop Eylea combination treatment http://uk.reuters.com/article/2014/01/13/regeneron-jointventure-idUKL3N0KN4CT20140113 New Laboratory Test Helps Hospitals Detect Newly Emerging Strains of Drug-Resistant Superbug http://bd.com/contentmanager/b_article.asp?Item_ID=27404&ContentType_ID=1&BusinessCode=20001&d=&s=press&dTitle=Press&dc=&dcTitle= January 10 Celgene Corporation to Present 2013 Unaudited Financial Results and Updated Financial Outlook at the 32nd Annual J.P. Morgan Healthcare Conference http://newsroom.celgene.com/press-release/corporate/celgene-corporation-present-2013-unaudited-financial-results-and-updated-fin Amicus Therapeutics to Present at 32nd Annual J.P. Morgan Healthcare Conference http://ir.amicustherapeutics.com/releasedetail.cfm?ReleaseID=818558 Merck to Present at the 32nd Annual J.P. Morgan Healthcare Conference http://www.mercknewsroom.com/news-release/corporate-news/merck-present-32nd-annual-jp-morgan-healthcare-conference January 9 Aerie Pharmaceuticals Reports Positive Results for Lead Candidate AR-13324 in Normotensive Individuals http://finance.yahoo.com/news/aerie-pharmaceuticals-reports-positive-results-120000922.html Senesco to Present at Biotech Showcase™ 2014 http://finance.yahoo.com/news/senesco-present-biotech-showcase-2014-120000669.html First Patient in Cohort 4 Receives Infusion of Senesco’s Therapeutic Candidate, SNS01-T, For the Treatment of Multiple Myeloma and Non-Hodgkins Lymphoma in Phase 1b/2a Clinical Trial http://finance.yahoo.com/news/first-patient-cohort-4-receives-121500703.html GSK gets accelerated FDA approval for melanoma drug combo http://www.reuters.com/article/2014/01/09/us-glaxosmithkline-cancer-idUSBREA0809T20140109 Soligenix to Present at the 2014 Biotech Showcase in San Francisco http://soligenix.com/news.aspx?titleId=443

10

January 8 Daclatasvir Marketing Authorization Application for Treatment of Chronic Hepatitis C Validated for Accelerated Regulatory Review by the European Medicines Agency http://news.bms.com/press-release/daclatasvir-marketing-authorization-application-treatment-chronic-hepatitis-c-validate Advaxis to Present at Biotech Showcase™ 2014 in San Francisco http://finance.yahoo.com/news/advaxis-present-biotech-showcase-2014-124500835.html Johnson & Johnson Innovation Expands Global Incubator Presence to Israel and Announces Multiple, Diverse, Early-Stage Collaborations with Academia and Biotech http://www.businesswire.com/news/home/20140108005519/en/Johnson-Johnson-Innovation-Expands-Global-Incubator-Presence NPS Pharmaceuticals Reports Preliminary 2013 Results and 2014 Financial Outlook http://www.businesswire.com/news/home/20140108005831/en/NPS-Pharmaceuticals-Reports-Preliminary-2013-Results-2014 Merck Receives FDA Approval for ISENTRESS®(raltegravir) for Pediatric Oral Suspension http://www.businesswire.com/news/home/20140108005210/en/Merck-Receives-FDA-Approval-ISENTRESS%C2%AE-raltegravir-Pediatric STENTYS Expands Marketing of its Stents in Asia http://www.businesswire.com/news/home/20140108005980/en/STENTYS-Expands-Marketing-Stents-Asia AstraZeneca and Bristol-Myers Squibb Announce U.S. FDA Approval of Farxiga™ (dapagliflozin) http://www.businesswire.com/news/home/20140108006657/en/AstraZeneca-Bristol-Myers-Squibb-Announce-U.S.-FDA-Approval Lexicon to Present at the JP Morgan Healthcare Conference http://www.lexpharma.com/news/press-releases/2310-2014-01-07-22-19-26.html January 7 ABRAXANE® Plus gemcitabine Receives European Marketing Authorization for First-Line Treatment of Patients with Metastatic Pancreatic Cancer http://newsroom.celgene.com/press-release/product/abraxane-plus-gemcitabine-receives-european-marketing-authorization-first-line The Medicines Company to Participate in Upcoming JP Morgan Healthcare Conference http://ir.themedicinescompany.com/phoenix.zhtml?c=122204&p=irol-newsArticle&ID=1888885&highlight= Lexicon to Present at the JP Morgan Healthcare Conference http://www.lexpharma.com/news/press-releases/2310-2014-01-07-22-19-26.html January 6 Antares Pharma to Present at the 32nd Annual J.P. Morgan Healthcare Conference http://finance.yahoo.com/news/antares-pharma-present-32nd-annual-180000424.html

11

Bristol-Myers Squibb to Announce Results for Fourth Quarter, Full Year 2013 on January 24 http://news.bms.com/press-release/financial-news/bristol-myers-squibb-announce-results-fourth-quarter-full-year-2013-jan Bristol-Myers Squibb to Present at J.P. Morgan Healthcare Conference http://news.bms.com/press-release/financial-news/bristol-myers-squibb-present-jp-morgan-healthcare-conference-3 PTC Therapeutics to Present at the J.P. Morgan Healthcare Conference http://ir.ptcbio.com/ReleaseDetail.cfm?ReleaseID=817249 Janssen Inks Up to $337.5M Cell Therapy Collaboration with Capricor http://www.genengnews.com/gen-news-highlights/janssen-inks-up-to-337-5m-cell-therapy-collaboration-with-capricor/81249320/ Cyclacel Pharmaceuticals to Present at Biotech Showcase(TM) 2014 Conference http://investor.cyclacel.com/releasedetail.cfm?ReleaseID=817059 Soligenix Appoints Richard Straube, MD, as Chief Medical Officer http://soligenix.com/news.aspx?titleId=442 January 3 NPS Pharmaceuticals Receives Orphan Drug Designation for Natpara® in Europe http://npsp.com/investors-pr?trxml_v=nrd&trxml_nr_id=1887693 26% of Drug Manufacturers have Chief Medical Officers in Place http://finance.yahoo.com/news/26-drug-manufacturers-chief-medical-133400421.html Thermo Fisher sells cell culture, other businesses to GE http://www.reuters.com/article/2014/01/06/us-thermofisher-sale-ge-idUSBREA050FS20140106?type=companyNews January 2 Celgene Corporation to Present at the 32nd Annual J.P. Morgan Healthcare Conference http://newsroom.celgene.com/press-release/corporate/celgene-corporation-present-32nd-annual-jp-morgan-healthcare-conference NPS Pharmaceuticals Initiates Global Registration Study of Teduglutide in Pediatric Patients with Short Bowel Syndrome http://npsp.com/investors-pr?trxml_v=nrd&trxml_nr_id=1887434 Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal 2014 Third Quarter Earnings http://investor.frx.com/press-release/corporate-news/forest-laboratories-inc-sets-date-and-conference-call-fiscal-2014-third December 30 Senesco Announces Letter of Intent to Merge with Fabrus http://finance.yahoo.com/news/senesco-announces-letter-intent-merge-135200062.html

12

Sanofi MS drug suffers setback in key U.S. market http://www.reuters.com/article/2013/12/30/sanofi-lemtrada-idUSL6N0K90UO20131230 Voluntary Field Corrective Action Initiated for Vital Signs Device’s CO2 Multi Absorber Due to a Health Risk http://www.businesswire.com/news/home/20131230005590/en/Voluntary-Field-Corrective-Action-Initiated-Vital-Signs Amicus Therapeutics Completes Debt Financing of Up to $25 Million -- Follows $15 Million Equity Financing http://files.shareholder.com/downloads/AMTX/2893799923x0x715762/b83ffba1-4c63-4d7d-8a7b-6e3bb098cbbf/FOLD_News_2013_12_30_General.pdf December 27 Regulatory Update on Cevira http://www.photocure.com/Pressmedia/News/Regulatory-Update-on-Cevira/ Lundbeck gets EU marketing approval for Brintellix http://www.reuters.com/article/2013/12/27/us-lundbeck-depression-idUSBRE9BQ0EC20131227 ThromboGenics’ JETREA® Receives Positive Common Drug Review in Canada http://thrombogenics.com/content/thrombogenics%E2%80%99-jetrea%C2%AE-receives-positive-common-drug-review-canada-0 December 26 TPG-Backed Drugmaker Aptalis Files for $500 Million U.S. IPO http://www.bloomberg.com/news/2013-12-26/tpg-backed-drugmaker-aptalis-files-for-500-million-u-s-ipo.html December 23 PTC Therapeutics Added to NASDAQ Biotechnology Index http://ir.ptcbio.com/ReleaseDetail.cfm?ReleaseID=815523 December 20 Antares Pharma® Announces Notice of Allowance for New Patent on Reconstitutable Lyophilized Injectables http://finance.yahoo.com/news/antares-pharma-announces-notice-allowance-120000939.html Zoetis to Host Webcast and Conference Call on Fourth Quarter and Full Year 2013 Financial Results http://www.thestreet.com/story/12162518/1/zoetis-to-host-webcast-and-conference-call-on-fourth-quarter-and-full-year-2013-financial-results.html Bayer raises offer for Xofigo partner Algeta http://www.pharmatimes.com/Article/13-12-20/Bayer_raises_offer_for_Xofigo_partner_Algeta.aspx

13

December 19 FDA Accepts For Review ELIQUIS®(apixaban) Supplemental New Drug Application for the Treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), and for the Reduction in the Risk of Recurrent DVT and PE http://news.bms.com/press-release/fda-accepts-review-eliquis-apixaban-supplemental-new-drug-application-treatment-deep-v December 18 Merck Collaborates with GlaxoSmithKline to Evaluate Novel Combination Regimen for Advanced Renal Cell Carcinoma http://www.mercknewsroom.com/news-release/research-and-development-news/merck-collaborates-glaxosmithkline-evaluate-novel-combina Bristol close to selling diabetes stake to Astra for $3 billion: WSJ http://www.reuters.com/article/2013/12/19/us-bristol-astrazeneca-idUSBRE9BI00O20131219 December 17 John Theurer Cancer Center Leadership in Blood Cancer Research Highlighted at the 55th Annual American Society of Hematology (ASH) Meeting in New Orleans http://www.bioportfolio.com/news/article/1758907/John-Theurer-Cancer-Center-Leadership-in-Blood-Cancer-Research-Highlighted-at-the.html Nautilus Neurosciences, Inc. Announces the Sale of CAMBIA® (Diclofenac Potassium for Oral Solution) to Depomed, Inc. for Total Consideration of Up to $53.7 Million http://www.businesswire.com/news/home/20131217006410/en/Nautilus-Neurosciences-Announces-Sale-CAMBIA%C2%AE-Diclofenac-Potassium MSD Animal Health Receives Positive Opinion from European Medicines Agency for BRAVECTO™ (fluralaner) http://www.mercknewsroom.com/news-release/corporate-news/msd-animal-health-receives-positive-opinion-european-medicines-agency-br Bristol-Myers Squibb Foundation Awards $3.28 Million in Grants to Support Mental Health Needs of U.S. Military Service Members Returning from Afghanistan and Iraq http://news.bms.com/press-release/philanthropy-news/bristol-myers-squibb-foundation-awards-328-million-grants-support-me December 16 Endo Health to acquire Nupathe for $105 million http://www.reuters.com/article/2013/12/16/us-nupathe-offer-idUSBRE9BF0LR20131216 Everett Laboratories acquires Quinnova Pharmaceuticals http://www.njbiz.com/article/20131216/NJBIZ01/131219779/Everett-Laboratories-acquires-Quinnova-Pharmaceuticals Click Here to return to the main page